C4 Therapeutics (CCCC) closed at $3.18 on October 22, 2026, up 0.3% from the previous close, on volume of 1,599,126 shares (30-day average 2,281,007).
Data as of October 22, 2026.
22-Oct-2026
Guggenheim Initiates a Buy Rating on C4 Therapeutics (CCCC)
TipRanks (Thu, 22-Oct 7:37 AM ET)
Market Chameleon (Tue, 20-Oct 7:31 AM ET)
Insmed Appoints Two New Directors to Its Board
PRNewswire (Tue, 20-Oct 7:00 AM ET)
Globe Newswire (Fri, 25-Sep 7:00 AM ET)
Globe Newswire (Thu, 3-Sep 7:00 AM ET)
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Tue, 11-Aug 7:00 AM ET)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 10-Aug 4:01 PM ET)
C4 Therapeutics Extends Cash Runway and Advances Cemsidomide as Phase 2 Clinical Trials Progress
Market Chameleon (Wed, 13-May 6:32 AM ET)
C4 Therapeutics Readies for Two Major March Conferences: What Investors Should Watch
Market Chameleon (Tue, 24-Feb 5:32 AM ET)
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
C4 Therapeutics trades on the NASDAQ stock market under the symbol CCCC.
As of October 22, 2026, CCCC stock price climbed to $3.18 with 1,599,126 million shares trading.
CCCC has a beta of 2.38, meaning it tends to be more sensitive to market movements. CCCC has a correlation of 0.17 to the broad based SPY ETF.
CCCC has a market cap of $391.22 million. This is considered a Small Cap stock.
Last quarter C4 Therapeutics reported $7 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.05.
In the last 3 years, CCCC traded as high as $11.88 and as low as $1.06.
The top ETF exchange traded funds that CCCC belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.
CCCC has outperformed the market in the last year with a price return of +39.5% while the SPY ETF gained +15.5%. However, in the short term, CCCC had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.0% vs +2.5% return in SPY. But in the last 2 weeks, CCCC shares have fared better than the market returning +11.6% compared to SPY -1.3%.
CCCC support price is $3.01 and resistance is $3.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CCCC shares will trade within this expected range on the day.
